Titre : Intégrines

Intégrines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cell Cycle Checkpoints
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Intégrines : Questions médicales les plus fréquentes", "headline": "Intégrines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Intégrines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-09", "dateModified": "2025-05-04", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Intégrines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Récepteurs immunologiques", "url": "https://questionsmedicales.fr/mesh/D011971", "about": { "@type": "MedicalCondition", "name": "Récepteurs immunologiques", "code": { "@type": "MedicalCode", "code": "D011971", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Intégrines alpha", "alternateName": "Integrin alpha Chains", "url": "https://questionsmedicales.fr/mesh/D039001", "about": { "@type": "MedicalCondition", "name": "Intégrines alpha", "code": { "@type": "MedicalCode", "code": "D039001", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.100" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Intégrine alpha1", "alternateName": "Integrin alpha1", "url": "https://questionsmedicales.fr/mesh/D039423", "about": { "@type": "MedicalCondition", "name": "Intégrine alpha1", "code": { "@type": "MedicalCode", "code": "D039423", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.100.300" } } }, { "@type": "MedicalWebPage", "name": "Intégrine alpha2", "alternateName": "Integrin alpha2", "url": "https://questionsmedicales.fr/mesh/D039421", "about": { "@type": "MedicalCondition", "name": "Intégrine alpha2", "code": { "@type": "MedicalCode", "code": "D039421", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.100.350" } } }, { "@type": "MedicalWebPage", "name": "Intégrine alpha3", "alternateName": "Integrin alpha3", "url": "https://questionsmedicales.fr/mesh/D039422", "about": { "@type": "MedicalCondition", "name": "Intégrine alpha3", "code": { "@type": "MedicalCode", "code": "D039422", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.100.400" } } }, { "@type": "MedicalWebPage", "name": "Intégrine alpha4", "alternateName": "Integrin alpha4", "url": "https://questionsmedicales.fr/mesh/D039441", "about": { "@type": "MedicalCondition", "name": "Intégrine alpha4", "code": { "@type": "MedicalCode", "code": "D039441", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.100.450" } } }, { "@type": "MedicalWebPage", "name": "Intégrine alpha5", "alternateName": "Integrin alpha5", "url": "https://questionsmedicales.fr/mesh/D039482", "about": { "@type": "MedicalCondition", "name": "Intégrine alpha5", "code": { "@type": "MedicalCode", "code": "D039482", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.100.500" } } }, { "@type": "MedicalWebPage", "name": "Intégrine alpha6", "alternateName": "Integrin alpha6", "url": "https://questionsmedicales.fr/mesh/D039503", "about": { "@type": "MedicalCondition", "name": "Intégrine alpha6", "code": { "@type": "MedicalCode", "code": "D039503", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.100.550" } } }, { "@type": "MedicalWebPage", "name": "Intégrine alphaV", "alternateName": "Integrin alphaV", "url": "https://questionsmedicales.fr/mesh/D039564", "about": { "@type": "MedicalCondition", "name": "Intégrine alphaV", "code": { "@type": "MedicalCode", "code": "D039564", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.100.900" } } }, { "@type": "MedicalWebPage", "name": "Glycoprotéine-IIb de membrane plaquettaire", "alternateName": "Platelet Membrane Glycoprotein IIb", "url": "https://questionsmedicales.fr/mesh/D040201", "about": { "@type": "MedicalCondition", "name": "Glycoprotéine-IIb de membrane plaquettaire", "code": { "@type": "MedicalCode", "code": "D040201", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.100.950" } } } ] }, { "@type": "MedicalWebPage", "name": "Chaines bêta des intégrines", "alternateName": "Integrin beta Chains", "url": "https://questionsmedicales.fr/mesh/D039641", "about": { "@type": "MedicalCondition", "name": "Chaines bêta des intégrines", "code": { "@type": "MedicalCode", "code": "D039641", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.200" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Antigènes CD29", "alternateName": "Integrin beta1", "url": "https://questionsmedicales.fr/mesh/D019012", "about": { "@type": "MedicalCondition", "name": "Antigènes CD29", "code": { "@type": "MedicalCode", "code": "D019012", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.200.500" } } }, { "@type": "MedicalWebPage", "name": "Intégrine bêta3", "alternateName": "Integrin beta3", "url": "https://questionsmedicales.fr/mesh/D039661", "about": { "@type": "MedicalCondition", "name": "Intégrine bêta3", "code": { "@type": "MedicalCode", "code": "D039661", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.200.750" } } }, { "@type": "MedicalWebPage", "name": "Intégrine bêta4", "alternateName": "Integrin beta4", "url": "https://questionsmedicales.fr/mesh/D039663", "about": { "@type": "MedicalCondition", "name": "Intégrine bêta4", "code": { "@type": "MedicalCode", "code": "D039663", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.200.800" } } } ] }, { "@type": "MedicalWebPage", "name": "Récepteur cytoadhésine", "alternateName": "Receptors, Cytoadhesin", "url": "https://questionsmedicales.fr/mesh/D016024", "about": { "@type": "MedicalCondition", "name": "Récepteur cytoadhésine", "code": { "@type": "MedicalCode", "code": "D016024", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.460" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Récepteur vitronectine", "alternateName": "Receptors, Vitronectin", "url": "https://questionsmedicales.fr/mesh/D019030", "about": { "@type": "MedicalCondition", "name": "Récepteur vitronectine", "code": { "@type": "MedicalCode", "code": "D019030", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.460.870" } } } ] }, { "@type": "MedicalWebPage", "name": "Récepteur du fibrinogène", "alternateName": "Receptors, Fibrinogen", "url": "https://questionsmedicales.fr/mesh/D039341", "about": { "@type": "MedicalCondition", "name": "Récepteur du fibrinogène", "code": { "@type": "MedicalCode", "code": "D039341", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.495" } } }, { "@type": "MedicalWebPage", "name": "Récepteur fibronectine", "alternateName": "Receptors, Fibronectin", "url": "https://questionsmedicales.fr/mesh/D017469", "about": { "@type": "MedicalCondition", "name": "Récepteur fibronectine", "code": { "@type": "MedicalCode", "code": "D017469", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.530" } } }, { "@type": "MedicalWebPage", "name": "Récepteur adhésion leucocytaire", "alternateName": "Receptors, Leukocyte-Adhesion", "url": "https://questionsmedicales.fr/mesh/D016028", "about": { "@type": "MedicalCondition", "name": "Récepteur adhésion leucocytaire", "code": { "@type": "MedicalCode", "code": "D016028", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.600" } } }, { "@type": "MedicalWebPage", "name": "Récepteur VLA", "alternateName": "Receptors, Very Late Antigen", "url": "https://questionsmedicales.fr/mesh/D016029", "about": { "@type": "MedicalCondition", "name": "Récepteur VLA", "code": { "@type": "MedicalCode", "code": "D016029", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.850" } } } ], "about": { "@type": "MedicalCondition", "name": "Intégrines", "alternateName": "Integrins", "code": { "@type": "MedicalCode", "code": "D016023", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Johanna Ivaska", "url": "https://questionsmedicales.fr/author/Johanna%20Ivaska", "affiliation": { "@type": "Organization", "name": "Turku Bioscience Center, University of Turku and Åbo Akademi University, FIN-20520 Turku, Finland; Department of Biochemistry, University of Turku, FIN-20520 Turku, Finland. Electronic address: joivaska@utu.fi." } }, { "@type": "Person", "name": "Jia Liu", "url": "https://questionsmedicales.fr/author/Jia%20Liu", "affiliation": { "@type": "Organization", "name": "Shenzhen Jiake Biotechnology, Shenzhen, China." } }, { "@type": "Person", "name": "Michael Bachmann", "url": "https://questionsmedicales.fr/author/Michael%20Bachmann", "affiliation": { "@type": "Organization", "name": "Department of Cell Physiology and Metabolism, University of Geneva, Centre Médical Universitaire, Rue Michel-Servet 1, 1211 Geneva 4, Switzerland." } }, { "@type": "Person", "name": "Vesa P Hytönen", "url": "https://questionsmedicales.fr/author/Vesa%20P%20Hyt%C3%B6nen", "affiliation": { "@type": "Organization", "name": "Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, FI-33520 Tampere, Finland." } }, { "@type": "Person", "name": "Bernhard Wehrle-Haller", "url": "https://questionsmedicales.fr/author/Bernhard%20Wehrle-Haller", "affiliation": { "@type": "Organization", "name": "Department of Cell Physiology and Metabolism, University of Geneva, Centre Médical Universitaire, Rue Michel-Servet 1, 1211 Geneva 4, Switzerland bernhard.wehrle-haller@unige.ch." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Revised mechanism of hydroxyurea-induced cell cycle arrest and an improved alternative.", "datePublished": "2024-10-07", "url": "https://questionsmedicales.fr/article/39374399", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1073/pnas.2404470121" } }, { "@type": "ScholarlyArticle", "name": "Cellular senescence: when growth stimulation meets cell cycle arrest.", "datePublished": "2023-02-19", "url": "https://questionsmedicales.fr/article/36805938", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.18632/aging.204543" } }, { "@type": "ScholarlyArticle", "name": "Marathon running and cell-cycle arrest biomarkers of acute kidney injury.", "datePublished": "2022-10-24", "url": "https://questionsmedicales.fr/article/36435729", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jsams.2022.10.012" } }, { "@type": "ScholarlyArticle", "name": "Ebselen Inhibits the Growth of Lung Cancer Cells via Cell Cycle Arrest and Cell Death Accompanied by Glutathione Depletion.", "datePublished": "2023-09-06", "url": "https://questionsmedicales.fr/article/37764247", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/molecules28186472" } }, { "@type": "ScholarlyArticle", "name": "Glabridin inhibits urothelial bladder carcinoma cell growth in vitro and in vivo by inducing cell apoptosis and cell cycle arrest.", "datePublished": "2022-09-26", "url": "https://questionsmedicales.fr/article/36098706", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/cbdd.14147" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Récepteurs de surface cellulaire", "item": "https://questionsmedicales.fr/mesh/D011956" }, { "@type": "ListItem", "position": 6, "name": "Récepteurs immunologiques", "item": "https://questionsmedicales.fr/mesh/D011971" }, { "@type": "ListItem", "position": 7, "name": "Intégrines", "item": "https://questionsmedicales.fr/mesh/D016023" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Intégrines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Intégrines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Intégrines", "description": "Comment diagnostiquer une dysfonction des intégrines ?\nQuels examens sont utilisés pour évaluer les intégrines ?\nLes biopsies sont-elles utiles pour les intégrines ?\nPeut-on détecter les intégrines par imagerie ?\nQuels marqueurs sont associés aux intégrines ?", "url": "https://questionsmedicales.fr/mesh/D016023?mesh_terms=Cell+Cycle+Checkpoints&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Intégrines", "description": "Quels symptômes indiquent une anomalie des intégrines ?\nLes troubles de la coagulation sont-ils liés aux intégrines ?\nComment les intégrines affectent-elles la cicatrisation ?\nLes douleurs articulaires peuvent-elles être liées aux intégrines ?\nY a-t-il des symptômes cutanés associés aux intégrines ?", "url": "https://questionsmedicales.fr/mesh/D016023?mesh_terms=Cell+Cycle+Checkpoints&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Intégrines", "description": "Peut-on prévenir les troubles liés aux intégrines ?\nLes vaccinations influencent-elles les intégrines ?\nL'exercice physique affecte-t-il les intégrines ?\nLe stress a-t-il un impact sur les intégrines ?\nLes habitudes alimentaires influencent-elles les intégrines ?", "url": "https://questionsmedicales.fr/mesh/D016023?mesh_terms=Cell+Cycle+Checkpoints&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Intégrines", "description": "Quels traitements ciblent les intégrines ?\nLes médicaments anti-inflammatoires aident-ils les intégrines ?\nLa thérapie génique peut-elle corriger les anomalies des intégrines ?\nLes greffes d'organes sont-elles affectées par les intégrines ?\nComment les intégrines sont-elles ciblées dans le cancer ?", "url": "https://questionsmedicales.fr/mesh/D016023?mesh_terms=Cell+Cycle+Checkpoints&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Intégrines", "description": "Quelles complications peuvent survenir avec des anomalies des intégrines ?\nLes anomalies des intégrines peuvent-elles causer des cancers ?\nComment les intégrines affectent-elles la santé cardiovasculaire ?\nLes complications cutanées sont-elles fréquentes avec les intégrines ?\nLes troubles neurologiques peuvent-ils être liés aux intégrines ?", "url": "https://questionsmedicales.fr/mesh/D016023?mesh_terms=Cell+Cycle+Checkpoints&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Intégrines", "description": "Quels facteurs augmentent le risque de troubles des intégrines ?\nL'âge influence-t-il la fonction des intégrines ?\nLe tabagisme affecte-t-il les intégrines ?\nLe diabète influence-t-il les intégrines ?\nLe stress oxydatif affecte-t-il les intégrines ?", "url": "https://questionsmedicales.fr/mesh/D016023?mesh_terms=Cell+Cycle+Checkpoints&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction des intégrines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de sang peuvent aider à diagnostiquer les anomalies des intégrines." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer les intégrines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'immunofluorescence et la cytométrie en flux sont couramment utilisés pour évaluer les intégrines." } }, { "@type": "Question", "name": "Les biopsies sont-elles utiles pour les intégrines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les biopsies peuvent révéler des anomalies d'expression des intégrines dans les tissus." } }, { "@type": "Question", "name": "Peut-on détecter les intégrines par imagerie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Certaines techniques d'imagerie moléculaire peuvent visualiser l'expression des intégrines." } }, { "@type": "Question", "name": "Quels marqueurs sont associés aux intégrines ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs comme CD29 et CD49 peuvent être utilisés pour identifier les intégrines." } }, { "@type": "Question", "name": "Quels symptômes indiquent une anomalie des intégrines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des problèmes d'adhésion cellulaire peuvent entraîner des inflammations et des infections récurrentes." } }, { "@type": "Question", "name": "Les troubles de la coagulation sont-ils liés aux intégrines ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies des intégrines peuvent provoquer des troubles de la coagulation sanguine." } }, { "@type": "Question", "name": "Comment les intégrines affectent-elles la cicatrisation ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les intégrines sont essentielles pour la migration cellulaire et la formation de nouveaux tissus lors de la cicatrisation." } }, { "@type": "Question", "name": "Les douleurs articulaires peuvent-elles être liées aux intégrines ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dysfonctionnements des intégrines peuvent contribuer à des douleurs articulaires et à l'arthrite." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés associés aux intégrines ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies des intégrines peuvent entraîner des maladies cutanées comme l'épidermolyse bulleuse." } }, { "@type": "Question", "name": "Peut-on prévenir les troubles liés aux intégrines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir certains troubles liés aux intégrines." } }, { "@type": "Question", "name": "Les vaccinations influencent-elles les intégrines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent moduler l'expression des intégrines, influençant la réponse immunitaire." } }, { "@type": "Question", "name": "L'exercice physique affecte-t-il les intégrines ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut améliorer la fonction des intégrines et la santé cellulaire." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur les intégrines ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut altérer l'expression des intégrines, affectant la santé immunitaire." } }, { "@type": "Question", "name": "Les habitudes alimentaires influencent-elles les intégrines ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants peut soutenir la fonction des intégrines et la santé cellulaire." } }, { "@type": "Question", "name": "Quels traitements ciblent les intégrines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies biologiques, comme les inhibiteurs d'intégrines, sont utilisées pour traiter certaines maladies auto-immunes." } }, { "@type": "Question", "name": "Les médicaments anti-inflammatoires aident-ils les intégrines ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les anti-inflammatoires peuvent réduire l'inflammation liée aux dysfonctionnements des intégrines." } }, { "@type": "Question", "name": "La thérapie génique peut-elle corriger les anomalies des intégrines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est une approche prometteuse pour corriger certaines anomalies des intégrines." } }, { "@type": "Question", "name": "Les greffes d'organes sont-elles affectées par les intégrines ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les intégrines jouent un rôle clé dans l'acceptation ou le rejet des greffes d'organes." } }, { "@type": "Question", "name": "Comment les intégrines sont-elles ciblées dans le cancer ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements ciblant les intégrines peuvent inhiber la métastase et la progression tumorale." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des anomalies des intégrines ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des infections récurrentes, des troubles de la coagulation et des maladies auto-immunes." } }, { "@type": "Question", "name": "Les anomalies des intégrines peuvent-elles causer des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies dans l'expression des intégrines sont associées à une augmentation du risque de cancer." } }, { "@type": "Question", "name": "Comment les intégrines affectent-elles la santé cardiovasculaire ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des dysfonctionnements des intégrines peuvent contribuer à des maladies cardiovasculaires et à l'athérosclérose." } }, { "@type": "Question", "name": "Les complications cutanées sont-elles fréquentes avec les intégrines ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies des intégrines peuvent entraîner des maladies cutanées graves comme l'épidermolyse." } }, { "@type": "Question", "name": "Les troubles neurologiques peuvent-ils être liés aux intégrines ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent un lien entre les anomalies des intégrines et des troubles neurologiques." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de troubles des intégrines ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs génétiques, des infections chroniques et des maladies auto-immunes augmentent le risque." } }, { "@type": "Question", "name": "L'âge influence-t-il la fonction des intégrines ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut altérer l'expression et la fonction des intégrines dans le corps." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il les intégrines ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut perturber l'expression des intégrines et affecter la santé cellulaire." } }, { "@type": "Question", "name": "Le diabète influence-t-il les intégrines ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut altérer la fonction des intégrines, augmentant le risque de complications." } }, { "@type": "Question", "name": "Le stress oxydatif affecte-t-il les intégrines ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress oxydatif peut endommager les intégrines et perturber leur fonction normale." } } ] } ] }

Sous-catégories

19 au total
└─

Intégrines alpha

Integrin alpha Chains D039001 - D12.776.543.750.705.408.100
└─

Chaines bêta des intégrines

Integrin beta Chains D039641 - D12.776.543.750.705.408.200
└─

Récepteur cytoadhésine

Receptors, Cytoadhesin D016024 - D12.776.543.750.705.408.460
└─

Récepteur du fibrinogène

Receptors, Fibrinogen D039341 - D12.776.543.750.705.408.495
└─

Récepteur fibronectine

Receptors, Fibronectin D017469 - D12.776.543.750.705.408.530
└─

Récepteur adhésion leucocytaire

Receptors, Leukocyte-Adhesion D016028 - D12.776.543.750.705.408.600
└─

Récepteur VLA

Receptors, Very Late Antigen D016029 - D12.776.543.750.705.408.850
└─└─

Intégrine alpha1

Integrin alpha1 D039423 - D12.776.543.750.705.408.100.300
└─└─

Intégrine alpha2

Integrin alpha2 D039421 - D12.776.543.750.705.408.100.350
└─└─

Intégrine alpha3

Integrin alpha3 D039422 - D12.776.543.750.705.408.100.400
└─└─

Intégrine alpha4

Integrin alpha4 D039441 - D12.776.543.750.705.408.100.450
└─└─

Intégrine alpha5

Integrin alpha5 D039482 - D12.776.543.750.705.408.100.500
└─└─

Intégrine alpha6

Integrin alpha6 D039503 - D12.776.543.750.705.408.100.550
└─└─

Intégrine alphaV

Integrin alphaV D039564 - D12.776.543.750.705.408.100.900
└─└─

Glycoprotéine-IIb de membrane plaquettaire

Platelet Membrane Glycoprotein IIb D040201 - D12.776.543.750.705.408.100.950
└─└─

Antigènes CD29

Integrin beta1 D019012 - D12.776.543.750.705.408.200.500
└─└─

Intégrine bêta3

Integrin beta3 D039661 - D12.776.543.750.705.408.200.750
└─└─

Intégrine bêta4

Integrin beta4 D039663 - D12.776.543.750.705.408.200.800
└─└─

Récepteur vitronectine

Receptors, Vitronectin D019030 - D12.776.543.750.705.408.460.870

Sources (10000 au total)

Marathon running and cell-cycle arrest biomarkers of acute kidney injury.

Endurance exercise is known to cause a rise in serum creatinine. It is not known to what extent this rise reflects renal stress and a potential acute kidney injury (AKI). Increases in Insulin Like Gro... Repeated measures study.... Runners were recruited at the 2019 Brighton Marathon (UK) and provided urine and blood samples at baseline, immediately post-race and 24 h post-race. Serum creatinine, urinary creatinine and urinary I... Seventy nine participants (23 females, 56 males), aged 43 ± 10 yrs. (mean ± SD), finish time 243 ± 40mins were included for analysis. Serum creatinine increased over the race by 40 ± 26% (p < 0.001), ... This study is the first to report large rises in IGFBP7 and TIMP-2 following marathon running. This suggests that rises in creatinine are not fully explained by changes in production and clearance and...

Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide.

Glioblastoma is the most aggressive form of brain cancer, characterised by high proliferation rates and cell invasiveness. Despite advances in surgery and radio-chemotherapy, patients continue to have... Here, the anticancer activity of quantum molecular resonance (QMR) was investigated. For this purpose, three glioblastoma cell lines were tested, and the QMR effect was evaluated on cancer cell prolif... QMR affected cancer cell proliferation, inducing a significant arrest of cell cycle progression and reducing cancer tumorigenicity. These parameters were not altered in healthy control cells. Proteomi... QMR technology appears to be a promising tool for glioblastoma treatment....

MIB2 promotes the progression of non-small cell lung cancer by regulating cell cycle control pathways.

Although numerous measures have been used to improve the outcome of lung cancer patients, lung cancer, as the second most common diagnosed cancer, is still the main cause of cancer death. It becomes i... The public databases were used to compare the expression level of MIB2 in cancer and non-cancer tissue. We analyzed the expression of MIB2 in lung cancer samples by performing Rt-PCR and western blot.... MIB2 is up regulated in lung cancer tissue compared to adjacent normal lung tissue according to both public databases and our clinical lung cancer samples. Knockdown of MIB2 inhibits proliferation, me... Our results prove that MIB2 acts as a driver in NSCLC tumorigenesis by regulating cell cycle control pathways....